Region Gaevleborg
- Address
- Rektorsgatan 1, 802 50 Gävle, Sweden
Neoplasms and Cancer Research at Region Gaevleborg
Clinical trials at this hospital-based site focus on neoplasms, with research centered on improving care for people with cutaneous malignant melanoma and small cell lung cancer. The studies are designed to evaluate new treatment approaches and better define how long immunotherapy should be used after surgery or alongside other cancer treatments.
- Testing whether shorter immunotherapy can provide similar benefit after surgery for high-risk melanoma
- Comparing combination treatment strategies for advanced small cell lung cancer against standard chemotherapy
- Assessing treatment effectiveness and survival outcomes in patients with advanced cancer
This work reflects a focused oncology program in Gavle that aims to improve survival and refine treatment choices for patients with difficult-to-treat cancers.
Lungenheten Cancer Studies in Sweden
At Lungenheten, the clinical trial portfolio is concentrated in oncology, with particular attention to skin cancer and lung cancer. The research is exploring whether newer treatment combinations can improve outcomes, while also helping clinicians understand the most effective duration and use of cancer therapy.
- Cutaneous malignant melanoma studies examining post-surgery immunotherapy
- Small cell lung cancer research evaluating a new treatment combination for advanced disease
- Clinical efforts aimed at improving overall survival and treatment effectiveness
With a small but targeted set of trials, the site contributes to practical advances in cancer care for patients in the Region Gaevleborg area.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 7 therapeutic areas and 15 of 57 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 53 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 20 by active trials.
- 1Vaestra Goetalandsregionen3active
lock +19 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Vaestra Goetalandsregionen4trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Gaevleborg
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized Controlled Trial Comparing Dapagliflozin Propanediol and Metformin in Early Stage Type 2 Diabetes for Mortality and Vascular Complications | Uppsala University | Phase III | Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 57 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 9 | Unknown | 2020-12-18 | 2026-06-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.